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Accepted 5 December 2018; Published online 8 December 2018AbstractObjectives: We reviewed measures used to estimate adherence and persistence to multiple cardiometabolic medications from prescrip-
tion data, particularly for blood pressure-lowering, lipid-lowering, and/or glucose-lowering medication, and give guidance on which mea-
sures to choose.
Study Design and Setting: A literature search of Medline, Embase, and PsycINFO databases was conducted to identify studies assess-
ing medication adherence and/or persistence for patients using multiple cardiometabolic medications. Two reviewers performed the study
selection process independently.
Results: From the 54 studies assessing adherence, only 36 (67%) clearly described the measures used. Five measures for adherence
were identified, including adherence to ‘‘all,’’ to ‘‘any,’’ to ‘‘both’’ medication, ‘‘average adherence,’’ and ‘‘highest/lowest adherence". From
the 22 studies assessing persistence, only six (27%) clearly described the measures used. Three measures for persistence were identified,
including persistence with ‘‘all,’’ with ‘‘both,’’ and with ‘‘any’’ medication. Less than half of the studies explicitly considered medication
switches when relevant.
Conclusion: From the identified measures, the ‘‘any medication’’ measure is most suitable for identifying patients in need of an inter-
vention, whereas the ‘‘all medication’’ measure is useful for assessing the effect of interventions. More attention is needed for adequate
measurement definitions when reporting on and interpreting adherence or persistence estimates to multiple medications.  2018 The Au-
thors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Keywords: Medication adherence; Persistence; Prescription data; Multiple cardiometabolic medications; Medication switch; Medication addition1. Introduction
Adherence and persistence to preventive medication are
known to be suboptimal in daily practice [1]. This is recog-
nized as a significant public health issue because medica-
tion nonadherence leads to poor health outcomes and
increased health care costs [2]. Medication adherence refers
to whether patients take their medications as prescribed,
whereas persistence refers to whether they continue to take
the medication [3]. As patient behavior is modifiable, it isConflict of interest statement: The authors of this article declare that
they do not have any conflict of interest related to the content of this
article.
* Corresponding author. Tel. þ31 (0)50-363-7576; fax: þ31 (0)50-
363-2772.
E-mail address: sofa.alfian@unpad.ac.id (S.D. Alfian).
https://doi.org/10.1016/j.jclinepi.2018.12.003
0895-4356/ 2018 The Authors. Published by Elsevier Inc. This is an open acc
licenses/by-nc-nd/4.0/).important to assess adherence and persistence, and subse-
quently develop interventions to improve their
medication-taking behaviors. However, most adherence
measurements in intervention trials were found of low qual-
ity, which may influence the precision of adherence rates
and subsequently lead to inefficient or even ineffective in-
terventions [4].
Because of the increase rate of polypharmacy [5], it be-
comes very relevant to monitor adherence and persistence
to multiple medications for the same indication. Adherence
assessment is more complex for these patients, particularly
when drugs can be switched or added over time. In addi-
tion, it is important to make a distinction between adher-
ence and persistence. Although these are related concepts,
they occur at different times of drug-taking behavior, that
is, in the implementation phase or the discontinuation phase
[3]. Only a patient who is still persistent (i.e., continuingess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 We identified five distinct measures to estimate
adherence and three distinct measures to estimate
persistence in patients using multiple medications
from prescription data, which can be used by future
adherence researchers.
 Many studies were flawed because of inadequate
description of the measures or how switching or
additions were dealt with.
What this adds to what was known?
 To our knowledge, this is a first study that system-
atically reviews the measures used to estimate
medication adherence and medication persistence
to multiple medications.
 This review extends previous literature on adher-
ence measures to multiple medications by identi-
fying distinct measures to estimate multiple
medications adherence and multiple medications
persistence that may lead to different estimates.
What is the implication and what should change
now?
 Researchers and practitioners need to be aware
of unclear or inadequate definitions of the adher-
ence and persistence measures when interpreting
results for patients using multiple medications
and targeting interventions to improve medica-
tion use.
 More attention is needed for providing adequate
measurement definitions in studies reporting on
adherence or persistence to multiple medications.
S.D. Alfian et al. / Journal of Clitherapy) can be nonadherent to a medication (i.e., taking
less medication) [3]. This distinction seems not always suf-
ficiently addressed when assessing adherence to multiple
medications [6,7].
The primary objective of this study is to systematically
review the measures that are used to calculate adherence
and persistence to multiple preventive medications from
prescription data and give guidance on when and why
one should choose one measure over another. We focus
on cardiometabolic medication, including blood pressure-
lowering, lipid-lowering, and glucose-lowering medication.
The secondary objective is to assess whether studies suffi-
ciently describe the measures used, particularly in relation
to addressing issues of switching and adding medication
at drug class or therapeutic level.2. Methods
We followed the Preferred Reporting Items for System-
atic Reviews and Meta-Analysis (PRISMA) [8] guideline to
report this systematic review. This systematic review was
registered in International Prospective Register of System-
atic Review (PROSPERO; www.crd.york.ac.uk) with regis-
tration number CRD42017069299.
2.1. Search strategy and selection criteria
A literature search ofMedline, Embase, and PsycINFO da-
tabases up to June 16, 2017 was conducted to identify studies
assessingmedication adherence and/or persistence tomultiple
cardiometabolic medications. The full search strategy using a
combination of medical subject heading terms and text words
can be found in the Supplementary data. In short, we included
experimental, cohort and case control studies among adults
(age 18 years or older) that calculated medication adherence
and/or persistence to multiple cardiometabolic oral medica-
tions (i.e., blood pressure-lowering, lipid-lowering, and/or
glucose-lowering medication) from prescription data (i.e.,
prescribing, dispensing, or claims databases) and were pub-
lished in English. Studies assessing adherence and/or persis-
tence to treatment guideline or to diet, predicting adherence
frommodel analysis, only focusing on primary nonadherence
(i.e., patients not obtaining the initial prescription), assessing
adherence and/or persistence frompill counts, self-report, pro-
vider or care-giver assessment, or from electronic monitoring
devices were excluded. Also, studies in which the adherence
and/or persistence measures were not described (i.e., measure
was either not defined or only referred to another article),
adherence and/or persistence measures produced non-
numeric values, and case reports or abstracts from conference
proceedings were excluded.
2.2. Review process
Eligibility assessment based on title and abstract was
conducted independently by two reviewers (SDA, ISP).
The full texts of potentially eligible articles were retrieved
and reviewed in the second stage of the screening process
by SDA and ISP. Disagreements between two reviewers
were resolved by consensus with a third reviewer (PD).
Inter-rater agreement in the title-abstract and full-text
screening was calculated using percent agreement and Co-
hen’s kappa (k) statistic. Data from the selected articles
were extracted by SDA, and any doubts from the data
extraction process were resolved by consensus with ISP.
We extracted the following information: country of study,
study design, period of study, research question, type of
data and/or database, characteristics of participants of the
study (inclusion/exclusion criteria), type of medication
studied, type of medication user studied (incident and/or
prevalent), sample size of source population, definition of
adherence and/or persistence (including the numerator
and denominator, type of methods used to assess adherence
46 S.D. Alfian et al. / Journal of Clinical Epidemiology 108 (2019) 44e53[e.g., proportion of days covered {PDC} or medication
possession ratio {MPR}], any defined cutoff points and in-
formation on incorporating medication switches and/or ad-
ditions at class or therapeutic level, when relevant),
association of adherence or persistence measures with clin-
ical outcomes (when presented), and funding sources.
We defined medication class level as including medica-
tion with a similar mechanism of action (e.g., sulfonylureas),
whereas therapeutic level was defined as including medica-
tion with similar pharmacological effects (e.g., glucose-
lowering medication). We classified the defined period for
the denominator in the adherence measures as prescription-
based or interval-based approach. The assessment period in
a prescription-based approach is defined as the number of
days between two prescriptions (variable period ending with
a prescription), whereas the period in an interval-based
approach is defined as the total number of days in the givenRecords identified through database 
searching, (n = 1,803)
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Fig. 1. Flow diagram of the systematic review process. *Several sinterval (fixed time interval). This distinction is relevant
because the interval-based approach may lead to underesti-
mating adherence when medication switches are not taken
into account. Incident users were defined as patients who
initiate medication of interest without prior use in a specified
period before the measurement period, whereas prevalent
users were defined as patients already taking a medication
of interest before the measurement period.2.3. Data analysis
Descriptive statistics were used to present proportions of
studies with particular characteristics. We determined at
study level whether measures of adherence and persistence
to multiple medications were clearly defined with regard to
the numerator and denominator. We also assessed whether
medication switches and additions were taken into account.Full-text articles excluded (n=116):
1. Medication adherence and/or persistence were 
not assessed, n=5
2. Medication adherence and/or persistence  were 
calculated from pill counts, self-report, provider 
or care-giver assessment, or electronic 
monitoring devices, n=3
3. Multiple medications were not assessed, n=63
4. Case reports, case studies, abstract conference, 
commentary, n=26
5. Combined monotherapy and multiple therapy, 
n=1
6. Adherence and/or persistence measures were 
incompletely described, n= 14
7. Non-English, n=4
Abstracts excluded (n =1,481):
1. Medication adherence and/or persistence were 
not assessed, n=1,104
2. Medication adherence and/or persistence were 
calculated from pill counts, self-report, provider 
or care-giver assessment, or electronic 
monitoring devices , n=16
3. Multiple medications were not assessed, n=90
4. Not used oral pills medication, n= 30
5. Not including blood pressure-lowering, lipid-
lowering or glucose lowering-drugs, n=112
6. Adherence and/or persistence were assessed to 
treatment guideline, diet, or predicting 
adherence and/or persistence from model 
analysis, n=60
7. The focus was primary adherence and/or 
persistence, n=3 
8. Qualitative study, n=2
9. Case reports, case studies, abstract conference,  
and commentary, n=64
tudies assessed adherence and persistence simultaneously.
Table 1. Characteristics of multiple medications adherence and/or
persistence studies
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Type of medication studied
Blood pressure-lowering 23 (36.5)3. Results
The literature search resulted in 1,803 records across three
databases. After removing duplicates, 1,660 abstracts were
screened and 179 were selected for full-text review. A total
of 63 articles met the eligibility criteria (Fig. 1). The inter-
rater agreement and reliability Cohen’s kappa after both
title-abstract and full-text screening were high (97.5% with
kappa 0.88, and 98.3% with kappa 0.93, respectively). The
most common medication evaluated was glucose-lowering
medication (n 5 26), followed by blood pressure-lowering
medication (n5 23). Most of the studies were conducted us-
ing prescription data from the United States (n 5 42). The
mean sample size of source population was 68,621 partici-
pants, ranging from 568 [9] to 706,032 [10] participants.
Table 1 summarizes characteristics of the studies. Study de-
tails from studies that clearly and not clearly described adher-
ence and persistence are presented in Table S1 and S2 in
Supplementary data, respectively.Lipid-lowering 3 (4.8)
Glucose-lowering 26 (41.3)
Combination of blood pressure-, lipid-,
and/or glucose-lowering medications
11 (17.5)
Type of medication users
Incident users 32 (50.8)
Prevalent users 21 (33.3)
Incident and prevalent users 10 (15.9)3.1. Multiple medications adherence measures
Of the 54 identified studies on adherence to multiple
medications, 36 studies (67%) clearly described the adher-
ence measures with MPR or PDC as the common methods.
In 31 of these 36 studies, switches or additions at class or
therapeutic level were possible. Only 16 of those studies
explicitly considered medication switches and/or additions
[6,7,10e23]. Most of 36 studies (n 5 23) looked at patients
who initiated with one or more of the medications of inter-
est [7,10e12,15e19,21e34]. Half of the studies (n 5 18)
used the interval-based approach [6,10,14,17e19,21,23,
24,27,28,30e36], whereas 16 studies used the
prescription-based approach [11e13,16,20,22,25,26,29,
37e43] and two studies used both the interval- and
prescription-based approach [7,15]. Of the 18 studies using
the interval-based approach, only six studies took medica-
tion switching into account [6,10,14,18,33,36].
Five distinct measures to estimate multiple medication
adherences were identified (Fig. 2).
First, measuring adherence to ‘‘all medications’’: Four
studies assessed adherence to each medication separately
and defined patients as being adherent when they had
collected at least 80% of each, that is, ‘‘all medications’’
[6,7,14,22]. All four studies assessed adherence to medica-
tion at class level, considering individual drugs within the
same medication class as interchangeable, and then calcu-
lated adherence to multiple classes at therapeutic level,
either for oral glucose-lowering [6,7,14] or blood
pressure-lowering medication [22].
Second, measuring adherence to ‘‘both medications’’:
Twelve studies assessed adherence to two medications, bycalculating the number of days when both medications
were available, which was indicated by concurrent pre-
scriptions [6,17,19,21,24,27,29e32,34,37]. Most of the
studies (n 5 11) used a value of 80% or higher to define
patients as adherent, whereas one study measured adher-
ence as a continuous variable. Eight studies assessed adher-
ence between two drugs or two classes from the same
therapeutic level (e.g., glyburide and metformin or angio-
tensin II receptor blockers and calcium channel blocker
[CCB]) [6,21,27,29,30,32,34,37]. Four studies assessed
adherence to two medications from different therapeutic
levels (e.g., CCB and statin) [17,19,24,31]. To define
whether drugs were considered as used concurrently, time
periods need to be defined to distinguish between concur-
rent use and a medication switch or a medication addition.
Only two studies stated this explicitly [17,21]. For example,
Ferrario et al. [21], used a period of at least 60 days before
discontinuation of index therapy to define a medication
addition for a blood pressure-lowering medication in a class
other than the index drug, whereas An and Nichol [17]
defined addition as medications prescribed to treat the co-
morbid conditions other than the index condition during
the 6-month period (index diabetes with comorbid hyper-
tension or vice versa).
Fig. 2. Methods to estimate multiple medications adherence.
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Twelve studies assessed adherence from number of days
with at least one medication available and defined patients
as being adherent when they had collected at least 80% of
one, that is, ‘‘any medication’’ [6,7,14,15,18,22e24,
28,33,35,38]. Also the studies using this measure first as-
sessed adherence for medication at class level and then
calculated adherence to multiple medication classes at ther-
apeutic level for glucose-lowering [6,7,14,18,33,38], blood
pressure-lowering [15,18,22e24,28,35], or lipid-lowering
medication [18,28]. Two of these studies validated the pro-
posed measure by assessing its association with clinical
outcomes. The study by Tang et al. [15] showed that adher-
ence to any blood pressure-lowering medication was
inversely associated with death (OR 5 0.70; 95% CI:
0.51e0.97). Fung et al. [35] showed that adherence to
any blood pressure-lowering medication was associated
with lower odds of having elevated systolic blood pressure
(OR 5 0.89; 95% CI: 0.85e0.93).Fourth, measuring adherence by calculating the
‘‘average’’ adherence: 19 studies assessed adherence by
first calculating adherence for the medication at individual
drug level [13,20,25,26,40,42,43] or class level
[6,7,10e12,14e16,35,36,39,41] and then calculate the
overall average. The most common medication evaluated
was glucose-lowering (n 5 13), followed by blood
pressure-lowering (n 5 3), and lipid-lowering (n 5 1)
medication. Most of the studies defined adherence as an
average level as 80% or more [6,7,10e16,20,25,
26,35,39,43], whereas four studies reported adherence as
a continuous variable [36,40e42]. Two of these studies
validated the proposed measure by assessing its association
with clinical outcomes. The study by Tang et al. [15]
showed that the average of the class-specific adherence
with an 80% cutoff level to blood pressure-lowering medi-
cation was inversely associated with death (OR 5 0.71;
95% CI: 0.53e0.95). Fung et al. [35] showed that the
average also with an 80% cutoff level to blood pressure-
49S.D. Alfian et al. / Journal of Clinical Epidemiology 108 (2019) 44e53lowering medication was associated with lower odds of
having elevated systolic blood pressure (OR 5 0.87; 95%
CI: 0.84e0.89).
Fifth, measuring the ‘‘highest’’ or ‘‘lowest’’ adherence:
One study assessed adherence to blood pressure-lowering
medication by calculating adherence for each medication
class, and then presented both the ‘‘highest’’ and the
‘‘lowest’’ as measure of adherence [15]. The study by Tang
et al. [15], however, showed that no significant association
was found between the highest or the lowest class-specific
adherence and death.3.2. Multiple medications persistence measures
Of the 22 identified studies on persistence to multiple
medications, six (27%) studies clearly described the persis-
tence measures. Only one of these studies clearly described
how they dealt with medication switches [44], where
switches at class or therapeutic level were possible for all
studies. Three distinct measures to estimate multiple medi-
cation persistence were identified (Fig. 3).
First, measuring persistence to ‘‘all medications’’: One
study calculated persistence to all medications and defined
patients as persistent when all medications were without a
medication gap of 30 days or more [45]. Persistence was
first assessed for individual drugs, and then overall persis-





Drug (class)  A
Start of interval
Drug (class) B
Nonpersistent when days with both 
30 days

















Initiation (day 1) 
Drug (class) B
Nonpersistent when there is no medication at treatment
Fig. 3. Methods to estimate multipfrom the same therapeutic level (e.g., metoprolol, hydro-
chlorothiazide, and amlodipine were without a medication
gap) [45].
Second, measuring persistence to ‘‘both medications’’:
Two studies assessed persistence for two medication classes
as follow: which days are covered by both classes (e.g.,
angiotensin II receptor blockers and CCBs) and identify
whether there is a gap without coverage of both classes. Pa-
tients are considered persistent if they have no such gaps in
both drug classes concurrently [30,34]. Zeng et al. [34]
used a 30-day permissible gap, whereas Hsu et al. [30] used
a 56-day gap to define persistence.
Third, measuring persistence to ‘‘any medication’’: Two
studies defined patients as being persistent when either drug
class A or drug class B from the same therapeutic level
were without a medication gap (e.g., 180 days gap)
[44,46]. In other words, patients were considered nonper-
sistent to blood pressure-lowering medication if they were
not receiving any blood pressure-lowering medication in a
period of more than 180 days since the last prescription
[44]. One study defined persistence to any medication by
using the treatment anniversary method, that is, assessing
whether or not patients are still receiving the medication
in 1 year after treatment initiation. Patients were considered
to be persistent if ‘‘any’’ (at least one) blood pressure-
lowering medication was still available on the 365th day af-
ter initiation [23].End of interval 
istent when at least one  drug  has a medication gap
(e.g drug A has gap ≥ 30 days)
30 days
End of interval 
drug A and drug B (grey blocks) have a gap ≥ 30 days gap
 for each patient
End of interval 
. no medication in period of 180 days)
Anniversary (day 365)
 anniversary (day 365)
le medications persistence.
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We reviewed the measures that have been proposed or
used to estimate medication adherence and medication
persistence to multiple cardiometabolic medications. Such
medication is usually intended for chronic use. From the
54 studies assessing adherence, only 36 (67%) clearly
described how they calculated adherence to multiple med-
ications. Five distinct adherence measures were identified
from these studies. Of the 31 studies in which switches or
additions at class or therapeutic level were possible, only
16 explicitly considered medication switches and/or addi-
tions. From the 22 studies assessing persistence, only six
(27%) clearly described how they calculated persistence
to multiple medications. Three distinct persistence mea-
sures were identified from these studies. Only one of the
studies explicitly considered medication switches, where
switches at class or therapeutic level were possible in all
studies.
Most of the included studies in this review were con-
ducted in the United States, which can in part be explained
by the wide availability of longitudinal databases with pre-
scriptions across a range of health care settings [47]. Most
of studies used 80% as a cutoff point to determine adher-
ence status, which is widely used and has shown to be a
reasonable cutoff point for single drug adherence based
on its ability of predicting subsequent hospitalization in
diabetes, hypertension, and hyperlipidemia patients [48].
This is a first systematic literature review summarizing
the measures used to calculate medication adherence and
medication persistence to multiple cardiometabolic medica-
tions. This review extends previous literature on adherence
measures to multiple medications [6,7], by identifying
distinct measures to estimate multiple medication adher-
ence and multiple medication persistence. Using disparate
definitions, these measures will result in different estimates
[6,7]. The ‘‘all medications’’ and ‘‘both medications’’ mea-
sures are very restrictive, in such a way that they will clas-
sify relatively few patients as adherent or persistent. The
‘‘all medications’’ measures were used in few studies,
whereas the ‘‘both medications’’ measures were used more
often, in particular to assess adherence and persistence to
concurrent medication from different class or therapeutic
levels. The ‘‘any medication’’ measure is likely to lead to
relatively high adherence or persistence rates because pa-
tients are classified as adherent or persistent when they
use only one of their drugs regularly. Use of the ‘‘any medi-
cation’’ adherence measure with an 80% cutoff level was
relatively common and showed to be associated with clin-
ical outcomes, indicating that it may be adequate for iden-
tifying clinically relevant nonadherence [15,35]. Also, the
‘‘average’’ adherence measure with an 80% cutoff level,
which will result in intermediate scores, was common
and showed to be associated with clinical outcomes
[15,35]. Both the ‘‘any medication’’ for adherence and
persistence measures and the ‘‘average’’ adherencemeasure should only be used to medication from the same
therapeutic level, assuming that these drugs are partly inter-
changeable regarding their therapeutic effects. The ‘‘high-
est’’ or ‘‘lowest’’ adherence measures showed not to be
associated with clinical outcomes [15]. These measures on-
ly reflect the adherence level to one drug and do not set a
benchmark by using cutoff level. As such, they seem more
difficult to interpret from a clinical perspective.
Adherence to individual drug classes or adherence to
any medication can be calculated with MPR or PDC for pa-
tients on multiple medications [15]. However, there is a
discrepancy between MPR and PDC methods when using
the ‘‘adherence to any’’ measure. Adding the days supply
for all medications in the numerator for the MPR may lead
to overestimating adherence, when a patient uses multiple
medications simultaneously or switches between medica-
tions with an overlap of the new drug with the prior drug
[49]. Because the PDC focusses on days with or without
medication, the presence of multiple medications on the
same day does not lead to such overestimations [49]. Thus,
PDC is preferred for calculating adherence to multiple
medications because of its lower risk of overestimation
[50,51]. Alternatively, Basak et al. proposed that switches
between equivalent agents should be carried forward, under
the assumption that the patient was supposed to consume
all medication, whereas switches between different thera-
peutic agents should not be carried forward, assuming that
the first treatment was to be discontinued at the time of the
switch [6]. We found that many studies that used the
interval-based approach to calculate adherence, however,
did not consider medication switches. This is a matter of
concern because the interval-based approach is likely to un-
derestimate adherence by classifying patients who switch
from one drug to another during the interval as being non-
adherent. This is supported by previous studies showing
that the interval-based approach provides lower adherence
estimates than the prescription-based approach [7,15].
This review can help researchers and practitioners in
choosing the measures to estimate medication adherence
and persistence to multiple medications from prescription
data. To identify patients for interventions to improve their
adherence, the ‘‘any medication’’ measure may be applied,
which is more sensitive to identify nonadherence. The
‘‘average adherence’’ and the ‘‘highest’’ or ‘‘lowest’’ adher-
ence measures are less suitable to identify patients for inter-
ventions. In the ‘‘average adherence’’ measure, the high
adherence to one medication may compensate poor adher-
ence to another medication and lead to an acceptable
average for the entire regimen. This measure has shown
to not only overestimate but also underestimate adherence
to multiple medications [52]. The ‘‘highest’’ or ‘‘lowest’’
adherence measures only reflect the adherence level to
one drug, thereby disregarding poor adherence to other
drugs. On the other hand, to measure the effect of interven-
tions to improve adherence, one may select a measure with
a high specificity, such as the ‘‘all medications’’ measure.
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based on the measures used [15,48]. For single medication
adherence, a threshold of 80% is commonly used. This may
also be appropriate when using the ‘‘any medication’’ mea-
sure [15]. In contrast, when using the more stringent ‘‘all
medication’’ or ‘‘both medications’’ adherence measures,
a lower threshold, such as 70%, might be preferred,
assuming that this is sufficient to achieve the desired clin-
ical effect. In addition, the association of adherence level
with clinical outcomes may also differ based on the dose
and type of medication used [53]. Higher adherence
threshold for low-dose medications might be preferred than
for high-dose medications to obtain a similar clinical effect.
In persistence studies, the focus can be either on persistence
of the initial medication/medication class or on any medi-
cation to treat a condition. To monitor whether patients
are still being treated for their condition, the ‘‘any medica-
tion’’ and ‘‘treatment anniversary’’ measures may suffice
because they are not restricted to a particular medication.
The ‘‘treatment anniversary’’ measure, however, is not sen-
sitive to early discontinuation followed by a restart before
the treatment anniversary. To measure the effect of inter-
ventions on persistence, one may select the more specific
‘‘all medication’’ measure.
Furthermore, we found that a substantial number of
studies were flawed because of inadequate description of
the methods or how switching or additions were dealt with.
More than 10 years ago, a checklist was developed for
medication adherence and persistence studies using retro-
spective databases, recommending the researchers to pro-
vide a rationale and/or a formula for studies using
multiple medications and explain how the analysis handled
patients who switched to another medication [54]. Our
study illustrates that the implementation of those recom-
mendations is still insufficient. Therefore, both authors
and reviewers of articles on adherence or persistence should
pay more attention that adequate measurement definitions
are provided. In addition, researchers and practitioners need
to be aware of these shortcomings when interpreting results
for patients using multiple medications. Both the quality of
the studies and the quality of the reporting will determine
whether appropriate interpretations can be made and rele-
vant interventions can be developed.
Some strengths and limitations of our review should be
mentioned. We conducted a systematic search using three
databases but only considered articles published in English
and studies using prescription data from prescribing,
dispensing, or claim databases (health insurance). We did
not include studies using electronic devices. The use of
multiple electronic devices is impractical for patients using
multiple medications. Therefore, it is usually decided to
monitor just one medication with electronic devices in in-
terventional studies, and hence there are too few studies us-
ing such data for multiple drug use. Two reviewers assessed
the study eligibility and the inter-rater agreement for this
was high. We found only two studies that analyzed theassociation of adherence or persistence measures with clin-
ical outcomes. Therefore, future studies are needed to vali-
date the various multiple medications adherence and
persistence measures with clinical outcomes. In addition,
more studies are needed comparing these prescription-
based measures with other methods to get better insight into
potential underestimations of adherence and persistence.
For example, linking prescription data with medical records
could reduce some of the risk of overestimating nonpersis-
tence when medication is stopped by the prescriber, and
reasons for stopping are documented.5. Conclusion
A variety of measures has been proposed or used to es-
timate adherence and persistence to multiple medications.
The ‘‘any medication’’ measure is helpful to monitor adher-
ence and persistence and to identify patients in need of an
intervention. The ‘‘all medication’’ measure is more useful
for assessing the effect of interventions. Many studies were
flawed because of inadequate description of methods or
how switching or additions were dealt with. Researchers
and practitioners need to be aware of these shortcomings
when interpreting results for patients using multiple medi-
cations. More attention is needed for providing adequate
measurement definitions in reporting on adherence or
persistence to multiple medications.Acknowledgment
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